| |
May 24, Sunday |
|
|
Registration |
Gamboa Rainforest Resort lobby |
|
|
|
Janine Hartfield, Nikki LeClair |
1700 |
|
Opening Ceremony |
Grand Ballroom |
|
|
John Adams |
Welcome to VMR3 conference |
|
|
Julio Escobar |
Secretary General of Science, Technology and Innovation |
1715 |
A1 |
Mario Rodriguez |
A new initiative to eradicate malaria in Mesoamerica |
1745 |
A2 |
Ric Price |
Challenges for eliminating P. vivax from the Asia-Pacific region |
1900 |
|
Opening reception |
Gamboa Rainforest Resort back patio |
| May 25, Monday |
| 630 |
breakfast buffet |
| The biology of vivax malaria and its vectors |
Chairs: Barbara Sina, Mario Rodriguez |
| 800 |
B1 |
John Adams |
VMR3 conference goals and agenda |
| 815 |
B2 |
Carlos Guerra |
A Preliminary map of the global distribution and intensity of transmission of Plasmodium vivax malaria |
| 845 |
B3 |
Dennis Shanks |
Planning for Malaria Elimination / Eradication especially Plasmodium vivax in Asia |
| 900 |
B4 |
AP Dash |
Vivax malaria: Indian Perspective |
| 915 |
B5 |
Goa Qi |
Susceptibility vivax to Anopheles anthrophagus from different areas in China |
| 930 |
B6 |
Jose Eduardo Calzada |
Genetic diversity studies of Plasmodium vivax circulating in Panamanian endemic areas |
| 945 |
B7 |
Chae Sung Lim |
The molecular characteristics of P. vivax in Korea isolated from 1996 to 2008. |
| 1000 |
|
|
break |
| 1030 |
B8 |
Akira Kaneko |
P. vivax resurgence a decade after malaria elimination on Aneityum island |
| 1045 |
B9 |
Ghulam Rahim Awab |
Comparative efficacy and safety of dihydroartimisinin-piperaquine (DHA-PQP) for the treatment of vivax malaria |
| in Afghanistan |
| 1100 |
B10 |
Sylvie Manguin |
Trend of vivax malaria in Southwest Asia for the past 40 years with a focus on Thailand and its malaria vectors. |
| 1115 |
B11 |
Robert Zimmerman |
Seasonal Abundance of Anopheline Mosquitoes and Their Association with rainfall and malaria along the Matapi River, Amapa, Brazil |
| 1130 |
B12 |
Yasmin Rubio-Palis |
Plasmodium vivax prevalence in anophelines from Venezuela |
| 1145 |
B13 |
Maria Mota |
Identification of host factors and lead compounds for development of novel agents targeting Plasmodium-infect hepatocytes – can they be used to target hypnozoite stages? |
| 1200 |
B14 |
TBA |
short talks |
| 1230 |
|
|
lunch in Los Guayacanes |
| Molecular & immunobiology of vivax malaria |
Chairs: Socrates Herrera, Ashis Das |
| 1400 |
C1 |
Nic Anstey |
How does P. vivax cause severe malaria? |
| 1430 |
C2 |
Socrates Herrera |
Plasmodium vivax CS Protein Clinical Trials in Colombia |
| 1445 |
C3 |
Luzia Carvalho |
Inhibitory antibodies to Plasmodium vivax Duffy binding protein are allele-specific following a single malaria infection |
| 1500 |
C4 |
Ivo Mueller |
Differential acquisition of immunity to P. vivax and |
| P. falciparum In Papua New Guinean children |
| 1515 |
C5 |
Chris King |
Correlates of Acquired Immunity to Plasmodium vivax |
| Duffy Binding Protein |
| 1530 |
C6 |
John Adams |
B-cell epitopes associated with naturally acquired inhibition of the Plasmodium vivax Duffy binding protein |
| 1545 |
C7 |
Osamu Kaneko |
P. vivax STP1 (SURFIN homolog) polymorphism and |
| human sera reactivity |
| 1600 |
|
|
break |
| 1630 |
C8 |
Balbir Singh |
Genetic diversity of P. knowlesi |
| 1645 |
C9 |
Peter Zimmerman |
Reduced susceptibility to Plasmodium vivax malaria in association with red blood cell polymorphisms |
| in Papua New Guinea |
| 1700 |
C10 |
Ashis Das |
Molecular analysis of Plasmodium vivax parasites involved in severe manifestations |
| 1715 |
C11 |
Liwang Cui |
Plasmodium vivax: global genetic diversity and local microheterogeneity |
| 1730 |
C12 |
YD Sharma |
Biochemical and Molecular Characterization of Aspartic protease gene (PvPM4) from Plasmodium vivax in India |
| 1745 |
C13 |
Kesinee Chotivanich |
P. vivax-infected red cells adhere to glycosaminoglycans |
| 1800 |
C14 |
TBA |
short talks |
| 1830 |
|
|
discussion groups |
| 1930 |
|
|
dinner |
| 2030 |
|
P1 |
posters |
| May 26, Tuesday |
| 630 |
|
|
breakfast buffet |
| Genomics and genetics of P. vivax |
Chairs: Jane Carlton, Hernando del Portillo |
| 800 |
|
John Adams |
today's agenda |
| 805 |
D1 |
Jane Carlton |
The study of Plasmodium vivax in the age of genomics |
| 830 |
D2 |
Zbynek Bozdech |
Comparative analyses of the Plasmodium vivax transcriptome to other Plasmodium species. |
| 845 |
D3 |
Nadira Karunaweera |
Microsatellite Diversity in Plasmodium vivax field parasite isolates |
| 900 |
D4 |
Marcelo Ferreira |
Population structure and evolution of Plasmodium vivax diversity in rural Amazonia |
| 915 |
D5 |
Ananis Escalante |
The evolution and distribution of primate malarias |
| in South East Asia |
| 930 |
D6 |
Lilia Gonzalez-Ceron |
Analysis of polymorphic genetic markers identified Plasmodium vivax relapeses of variable interval time in a malaria transmission focus of Southern Chiapas, Mexico |
| 945 |
D7 |
Jung-Yeon Kim |
Long-term and multiple analysis of genetic diversity on |
| re-emerged P. vivax in Korean peninsula: |
| current malaria is endemic? |
| 1000 |
|
|
break |
| 1030 |
D8 |
Rick Fairhurst |
Does hemoglobin E influence the pathogenesis |
| of P. vivax malaria? |
| 1045 |
D9 |
Anavaj Sakuntabhai |
Human Genetic susceptibility to Plasmodium vivax |
| 1100 |
D10 |
Hernando del Portillo |
Role of the spleen in reticulocyte-prone non lethal malaria |
| 1115 |
D11 |
Peter Preiser |
Understanding the biological role of the pir multigene family |
| in Plasmodium. |
| 1130 |
D12 |
David Roos |
PlasmoDB: New data, new features, and new functionality |
| for data mining |
| 1200 |
D13 |
TBA |
short talk |
| 1230 |
|
|
lunch in Los Guayacanes |
| Obstacles & opportunities for P. vivax drug therapy |
Chairs: Qin Cheng, Nicanor Obaldia |
| 1400 |
E1 |
Ric Price |
Chloroquine-Resistance is emerging on the |
| Thai Myanmar border |
| 1430 |
E2 |
Marcus Lacerda |
Treatment of Vivax Malaria in Latin America |
| 1445 |
E3 |
Jae-Won Park |
Changing Pattern of chloroquine- susceptibility of |
| Plasmodium vivax in the Republic of Korea |
| 1500 |
E4 |
Qin Cheng |
Dissecting Drug Resistance in P. vivax |
| 1515 |
E5 |
Chairat Uthaipibul |
Plasmodium models for anti-P. vivax DHFR-TS screening |
| 1530 |
E6 |
Carmenza Spadafora |
ICBG natural products drug discovery program for new antimalarials |
| 1545 |
E7 |
Nicanor Obaldia |
Evaluation of Drug and Vaccine candidates in the Human |
| P. falciparum and P. vivax Malaria/Aotus Monkey model |
| 1600 |
|
|
break |
| 1630 |
E8 |
Dennis Kyle |
Opportunities for liver stage drug development |
| 1700 |
E9 |
Clemens Kocken |
Plasmodium cynomolgi: in vivo and in vitro models for |
| P. vivax liver stage drug development |
| 1715 |
E10 |
Dominique Mazier |
Towards a rational design of a hepatocyte cell line permissive to complete maturation of P. falciparum and P. cynomolgi |
| 1730 |
E11 |
Soundarapandian Velmurugan |
New Tools for Attacking the Liver Stage of Plasmodium vivax |
| 1745 |
E12 |
Jetsum Prachumsri |
Research on the Plasmodium vivax parasite to support drug and vaccine development |
| 1800 |
E13 |
Geoffery Dow |
Radical Cure and Anti-Relapse Efficacy of Tafenoquine Drug Combinations Against P. cynomolgi Malaria |
| in Rhesus Macaques |
| 1800 |
E14 |
Wil Milhous |
Summary: how did we get to where we are? |
| 1815 |
E15 |
TBA |
short talk |
| 1830 |
|
|
discussion groups |
| 1930 |
|
|
dinner |
| 2030 |
|
P2 |
poster session |
| sponsored by the Gorgas Memorial Institute |
| May 27, Wednesday |
| 630 |
breakfast buffet |
| Vaccines, clinical trials, models |
Chairs: Laurent Renia, Yimin Wu |
| 800 |
|
John Adams |
today's agenda |
| 805 |
F1 |
John Barnwell |
Some New Non-human Primate Models for Vivax Malaria Research and How to evaluate P vivax vaccines |
| 830 |
F2 |
Myriam Arevalo-Herrera |
Aotus model as a model for Plasmodium vivax vaccine studies |
| 845 |
F3 |
Ruobing Wang |
Vivax Malaria Vaccine Development: taking cues from nature |
| 900 |
F4 |
Laurent Renia |
Plasmodium vivax immunity: identifying correlates of protection & Exploring the Nanoterrain and Biomechanics |
| of P. vivax IRBCs |
| 915 |
F5 |
Maricio Rodrigues |
New malaria vaccine candidates based on the Plasmodium Merozoite Surface Protein-1 and the innate immune response agonist Salmonella typhimurium FliC flagellin |
| 930 |
F6 |
Anjali Yadava |
Pre-Clinical Development of a Pre-erythrocytic vaccine |
| for P. vivax |
| 945 |
F7 |
Jon Daugherty |
Regulatory Perspectives on Plasmodium vivax Malaria |
| Vaccine Development |
| 1000 |
|
|
break |
| 1030 |
F8 |
Takafumi Tsuboi |
Wheat germ cell-free protein synthesis system: a breakthrough for the post-genome malaria vaccine candidate discovery |
| 1045 |
F9 |
Mary Galinski |
P. vivax target discovery: the promise and perils of in vivo |
| and in vitro models |
| 1100 |
F10 |
Niraj Tolia |
Dimerization is important for the interaction of P. vivax Duffy binding proteiin with the host receptor Duffy Antigen Receptor for Chemokines |
| 1115 |
F11 |
Yimin Wu |
Transmission Blocking Vaccine for Vivax Malaria |
| 1130 |
F12 |
Joe Vinetz |
Designing Transmission-Blocking Malaria Vaccine Trials for Plasmodium vivax malaria |
| 1145 |
F13 |
TBA |
short talks |
| 1230 |
|
|
lunch |
| 1830 |
|
|
discussion groups |
| 1230 |
|
|
lunch |
| 2030 |
|
culture workshop |
Kesinee Chatovanich, Tetsuya Furuya, Qi Gao, Eun-Taek Han, Tasanee Panichakul, Ubalee Ratawan, Louis Schofoeld, Nongnuch Yimamnuaychoke |
| 2030 |
|
bioinformatic workshop |
Omar Harb |
| May 28, Thursday |
| 630 |
|
|
breakfast buffet |
| |
Community resources |
Chairs: Jane Carlton, Barbara Sina |
| 800 |
|
John Adams |
today's agenda |
| 810 |
|
various |
funding mechanisms for research & training: NIH, WHO, MMV, MVI, BMGF, WT |
| |
|
various |
community networking and support groups |
| |
|
TBA |
other resources for the research community |
| 1000 |
|
|
break |
|
Summary |
John Adams |
| 1030 |
| |
|
focus groups |
epidemiology, vectors, envirnmental control |
| |
|
|
diagnosis, clinical management |
| |
|
|
immunity preclinical discovery, vaccine development |
| |
|
|
drugs, resistance,target , development |
| 1230 |
|
|
lunch |
| 1400 |
|
|
final chance to network and plan collaborative studies |
| Conference program will end at 2 PM. |
 |